116 related articles for article (PubMed ID: 23196678)
21. [The application of
Tang MT; Zeng XY; Li Y; Sun HT; Liu SY; Yuan X; Lu W
Zhonghua Yan Ke Za Zhi; 2021 Nov; 57(11):830-836. PubMed ID: 34743468
[No Abstract] [Full Text] [Related]
22. Application of quantitative orbital analysis to assess the activity of Graves' ophthalmopathy.
Li S; Liu YJ
Am J Nucl Med Mol Imaging; 2023; 13(6):259-268. PubMed ID: 38204608
[TBL] [Abstract][Full Text] [Related]
23. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study.
Erdei A; Paragh G; Kovacs P; Karanyi Z; Berenyi E; Galuska L; Lenkey A; Szabados L; Gyory F; Ujhelyi B; Berta A; Boda J; Berta E; Bodor M; Gazdag A; Nagy EV
Autoimmunity; 2014 Dec; 47(8):548-55. PubMed ID: 25039242
[TBL] [Abstract][Full Text] [Related]
24. Early Stage Graves' Disease is Uniformly Accompanied by Orbital Immune Activity even in Patients who Fail to Develop Orbithopathy during Follow-up.
Berta E; Bodor M; Galuska L; Paragh G; Erdei A; Gazdag A; Ujhelyi B; Berényi E; Katkó M; Gazsó A; Nagy EV
Exp Clin Endocrinol Diabetes; 2018 Nov; 126(10):628-631. PubMed ID: 29388175
[TBL] [Abstract][Full Text] [Related]
25. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
[TBL] [Abstract][Full Text] [Related]
26. Active retrobulbar inflammation in Graves' ophthalmopathy visualized by Tc-99m DTPA SPECT.
Galuska L; Varga J; Szucs Farkas Z; Garai I; Boda J; Szabo J; Leovey A; Nagy EV
Clin Nucl Med; 2003 Jun; 28(6):515-6. PubMed ID: 12917542
[No Abstract] [Full Text] [Related]
27. Correlation of 99mTc-DTPA SPECT of the blood-brain barrier with neurologic outcome after acute stroke.
Lorberboym M; Lampl Y; Sadeh M
J Nucl Med; 2003 Dec; 44(12):1898-904. PubMed ID: 14660714
[TBL] [Abstract][Full Text] [Related]
28. Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.
Ma Z; Ozaki H; Ishikawa Y; Jingu K
Jpn J Radiol; 2019 Aug; 37(8):612-618. PubMed ID: 31201593
[TBL] [Abstract][Full Text] [Related]
29. Orbital radiation therapy for Graves' ophthalmopathy: measuring clinical efficacy and impact.
Hahn E; Laperriere N; Millar BA; Oestreicher J; McGowan H; Krema H; Gill H; DeAngelis D; Hurwitz J; Tucker N; Simpson R; Chung C
Pract Radiat Oncol; 2014; 4(4):233-9. PubMed ID: 25012831
[TBL] [Abstract][Full Text] [Related]
30. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
31. Optic neuropathy following orbital irradiation for Graves' ophthalmopathy: a case report and literature review.
Sánchez-Orgaz M; Grabowska A; Royo-Oreja A; Asencio-Durán M; Romero-Martín R; Arbizu-Duralde A
Orbit; 2012 Feb; 31(1):30-3. PubMed ID: 22029640
[TBL] [Abstract][Full Text] [Related]
32. Tc-99m polyclonal human immunoglobulin G imaging in Graves' ophthalmopathy.
Durak H; Söylev M; Durak I; Değirmenci B; Capa Kaya G; Uysal B
Clin Nucl Med; 2000 Sep; 25(9):704-7. PubMed ID: 10983759
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of (99m)Tc-EDDA/HYNIC-TOC SPECT/CT scintigraphy in Graves' ophthalmopathy.
Zhao R; Wang J; Deng J; Yang W; Wang J
Am J Nucl Med Mol Imaging; 2012; 2(2):242-7. PubMed ID: 23133815
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of graves' ophthalmopathy treated with intensity modulated radiation therapy.
Li YJ; Luo Y; He WM; Li P; Wang F
Radiat Oncol; 2017 Nov; 12(1):171. PubMed ID: 29110673
[TBL] [Abstract][Full Text] [Related]
35. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology.
Bradley EA; Gower EW; Bradley DJ; Meyer DR; Cahill KV; Custer PL; Holck DE; Woog JJ
Ophthalmology; 2008 Feb; 115(2):398-409. PubMed ID: 18082885
[TBL] [Abstract][Full Text] [Related]
36. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
[TBL] [Abstract][Full Text] [Related]
37. [Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy].
Duan L; Li XF; Lu KY; Zhang CG; Hu G; Liu JZ; Li SJ
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1068-72. PubMed ID: 17415962
[TBL] [Abstract][Full Text] [Related]
38. Classification of orbital morphology for decompression surgery in Graves' orbitopathy: two-dimensional versus three-dimensional orbital parameters.
Borumandi F; Hammer B; Noser H; Kamer L
Br J Ophthalmol; 2013 May; 97(5):659-62. PubMed ID: 23428985
[TBL] [Abstract][Full Text] [Related]
39. Echographic monitoring of response of extraocular muscles to irradiation in Graves' ophthalmopathy.
Erickson BA; Harris GJ; Lewandowski MF; Murray KJ; Massaro BM
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):651-60. PubMed ID: 7852132
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of radiation therapy in the treatment of Graves' orbitopathy.
Matthiesen C; Thompson JS; Thompson D; Farris B; Wilkes B; Ahmad S; Herman T; Bogardus C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):117-23. PubMed ID: 21030157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
